Related Experiment Videos
Vaccines in AIDS. Present state of knowledge
1Immuno AG, Biomedical Research Center, Orth/Donau, Austria.
International Archives of Allergy and Immunology
|January 1, 1993
Summary
Developing an effective vaccine against Human Immunodeficiency Virus type 1 (HIV-1), the cause of AIDS, is a critical goal. Early research showed promise in preventing HIV-1 infection in chimpanzees, leading to human trials for both prevention and treatment.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).
- The development of prophylactic and therapeutic vaccines against HIV-1 is a major global health priority.
Purpose of the Study:
- To review the progress in developing HIV-1 vaccines.
- To describe various vaccine strategies and their outcomes in preclinical and clinical studies.
Main Methods:
- Preclinical studies involving candidate vaccines in chimpanzee models.
- Initiation and monitoring of human clinical trials in HIV-1 seronegative and seropositive individuals.
Main Results:
- Initial findings demonstrated that some candidate vaccines could prevent HIV-1 infection in chimpanzees.
- Human trials have commenced, evaluating different vaccine strategies in diverse populations.
Conclusions:
- Significant advancements have been made in HIV-1 vaccine development, moving from animal models to human trials.
- Ongoing research and clinical trials are crucial for achieving an effective AIDS vaccine.